Frugal design brings medical innovations to communities that lack resources during the pandemic
theconversation.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theconversation.com Daily Mail and Mail on Sunday newspapers.
A new wave : Concern in Switzerland as Covid numbers continue to climb
thelocal.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelocal.ch Daily Mail and Mail on Sunday newspapers.
Antibody Mediated Prevention (AMP) trials data published by the
New England Journal of Medicine
Most advanced clinical trials testing broadly neutralizing antibody against HIV demonstrate efficacy against sensitive strains
Public Relations Pacific LLC
E-Mail
SEATTLE - (EMBARGOED UNTIL MARCH 17, 2021, AT 5 P.M. ET) - The proof-of-concept AMP studies demonstrated that a broadly neutralizing antibody (bnAb) called VRC01 was effective at preventing the acquisition of HIV strains to the 30% of strains that were sensitive to the bnAb. This finding was seen both in Sub-Saharan Africa and the U.S. and South America. VRCO1 did not prevent the acquisition of HIV to strains that were resistant to the bNAb. As the resistant strains constituted nearly 70% of the circulating strains in these regions, there was no difference noted between the VRC01 arms and placebo arm in terms of overall prevention of HIV acquisition. The sensitivity to bNAbs was assessed by a laborat